Crinetics PharmaceuticalsCRNX
About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Employees: 437
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
159% more call options, than puts
Call options by funds: $1.7M | Put options by funds: $654K
71% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 65
68% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 22
18% more capital invested
Capital invested by funds: $4.32B [Q3] → $5.1B (+$775M) [Q4]
17% more funds holding in top 10
Funds holding in top 10: 12 [Q3] → 14 (+2) [Q4]
5% more funds holding
Funds holding: 233 [Q3] → 244 (+11) [Q4]
1.89% more ownership
Funds ownership: 105.58% [Q3] → 107.47% (+1.89%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Stifel Alex Thompson 43% 1-year accuracy 3 / 7 met price target | 99%upside $60 | Buy Initiated | 25 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 34% 1-year accuracy 23 / 67 met price target | 202%upside $91 | Market Outperform Maintained | 28 Feb 2025 |
Jefferies Dennis Ding 0% 1-year accuracy 0 / 5 met price target | 82%upside $55 | Buy Upgraded | 22 Jan 2025 |
Financial journalist opinion
Based on 4 articles about CRNX published over the past 30 days









